ABOS — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
Acumen’s Q2 2026 net loss narrowed to $32.7M as Alzheimer’s trial manufacturing costs fell, but $110.2M of cash lasts only into early 2027, triggering a going-concern warning ahead of late-2026 ALTITUDE-AD results.
- Net income
- -$33M
- -20.1% YoY
- Diluted EPS
- $-0.45
- -33.8% YoY
Acumen Pharmaceuticals, a clinical-stage biotech with no product revenue, lost $32.7 million in the second quarter of 2026, down from $41.0 million a year earlier. The smaller loss came mostly from lower drug-manufacturing and trial-management bills for its Phase 2 Alzheimer's study, ALTITUDE-AD, partly offset by a one-time $9.3 million option payment to Japanese partner JCR Pharmaceuticals. The bigger story is the balance sheet: the company ended June with $110.2 million in cash and short-term investments, says that money lasts only "into early 2027", and has concluded there is "substantial doubt" about its ability to continue as a going concern. The top-line readout of ALTITUDE-AD, expected in late 2026, lands just before that cash runs out.
At a glance
- $110.2 million in cash and investments (down from $128.4 million at the end of March): enough, per management, to run the company into early 2027, which is less than the 12 months accounting rules require for a clean bill of health.
- $18.1 million cash burn in the quarter (operating cash outflow, our calculation from the six-month and three-month cash flow statements): about half the pace of a year ago, because the expensive trial-supply manufacturing is largely done.
- Late 2026: ALTITUDE-AD top-line results for sabirnetug, the company's only clinical-stage drug. For a company at this stage, that single readout decides whether it can raise more money on reasonable terms.
What Acumen does, briefly
Acumen is developing sabirnetug, an antibody given by IV infusion every four weeks that is designed to latch onto amyloid-beta oligomers: small, soluble clumps of a protein that the company believes are a main toxic driver of Alzheimer's disease. That differs from the approved Alzheimer's antibodies, which mainly clear the larger amyloid plaques. ALTITUDE-AD is a randomized, placebo-controlled trial of 542 people with mild cognitive impairment or mild dementia due to Alzheimer's, testing two doses (35 mg/kg and 50 mg/kg). The main measure is the change on the iADRS memory-and-daily-function scale after 18 months versus placebo; the company will also report CDR-SB (another standard dementia score) and rates of ARIA, the brain swelling or micro-bleeding side effect seen with this drug class.
A second, earlier-stage program pairs Acumen's antibodies with JCR's blood-brain-barrier technology (called Enhanced Brain Delivery, or EBD), aiming to get more drug into the brain. In June 2026 Acumen picked two development candidates, ACU301 and ACU401, and is targeting an IND (the application needed to start human trials) for the lead one in .